Eduardo Magalhães Rego

Author

Also Known As

Bob Löwenberg, E M Rego, E Magalhães Rego, E Rego, E. Hesper Rego, E. M Rego, E. M. REGO, E. M. Rego, E. Magalhães Rego, E. Rego

648

Publications

8.2K

Citations

H-Index

123

Concepts

All Affiliations

Universidade de São Paulo Universidade Estadual de Campinas (UNICAMP)Clinics Hospital of Ribeirão Preto Universidade Federal de Pernambuco Memorial Sloan Kettering Cancer Center

About

Eduardo Magalhães Rego is an author at Universidade de São Paulo specializing in medicine, hematology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	27	47	2.9K
2	Health Sciences	8	8	255
3	Public Health	3	3	83
4	Engineering	2	2	489
5	Natural Sciences	2	2	456

Eduardo Magalhães Rego

108

Publications

5.3K

Citations

H-Index

Page 1

	Year	Citations
Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency Maria Barna, Aya D. Pusic, Ornella Zollo, Nature ChromatinOncogenic AgentNatural SciencesMolecular BiologyRibosomal Protein Haploinsufficiency	2008	424
Dyskeratosis Congenita and Cancer in Mice Deficient in Ribosomal RNA Modification Davide Ruggero, Silvia Grisendi, Francesco Piazza, Science Genome InstabilityEngineeringRibosomal Rna ModificationDyskeratosis CongenitaRibosomal Rna Pseudouridylation	2003	422
Impaired Control of IRES-Mediated Translation in X-Linked Dyskeratosis Congenita Andrew Yoon, Guang Peng, Yves Brandenburg, Science	2006	413
Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer Shuo Wei, Shingo Kozono, Lev M. Kats, Nature Medicine Active Pin1Mixed-phenotype Acute LeukemiaBreast CancerTumor SuppressorRadiation Oncology	2015	265
Retinoic acid (RA) and As <sub>2</sub> O <sub>3</sub> treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARα and PLZF-RARα oncoproteins Eduardo Magalhães Rego, Li-Zhen He, Raymond P. Warrell, Proceedings of the National Academy of Sciences Mixed-phenotype Acute LeukemiaImmunologyRetinoic AcidCell DeathTumor Biology	2000	194
Role of Promyelocytic Leukemia (Pml) Protein in Tumor Suppression Eduardo Magalhães Rego, Zhugang Wang, Daniela Peruzzi, The Journal of Experimental Medicine Leukemia PathogenesisMixed-phenotype Acute LeukemiaApoptosisCell DeathCancer Biology	2001	155
Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL Eduardo Magalhães Rego, Haesook T. Kim, Guillermo J. Ruíz‐Argüelles, Blood	2013	148
Two Critical Hits for Promyelocytic Leukemia Li-Zhen He, Mantu Bhaumik, Carla Tribioli, Molecular Cell Hematological MalignancyMedicineMixed-phenotype Acute LeukemiaMalignant Blood DisorderHematology	2000	144
Identification of a myeloid committed progenitor as the cancer-initiating cell in acute promyelocytic leukemia Florence C. Guibal, Meritxell Alberich-Jordà, Hideyo Hirai, Blood	2009	127
FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk Michele Spina, Zoltán Nagy, Josep‐María Ribera, Annals of Oncology Lymphoid NeoplasiaUrologyFebuxostat Versus AllopurinolMedicineKidney Failure	2015	84

Page 1